interesting buy - stock has gotten crushed after ~30% or more CMS cut to eqpt they sell - could be a value trap unless LNCR finds a way to capitalize on this as smaller operators are unable to deal with cuts and ultimately fold, so LNCR, if it survives, could gain share
Specialty Pharmacies Play Growing Role in Patient Care [View article]
employers are having issues understanding thier true speciality PMPM cost so upside for these guys in that vein. On the st, lots of investors waiting for clarity on biosimilars bill/waxman moves. Specialty unit costs help off set top line being lowered by generic substitution.
Teva and Walgreen: Two Solid Value Companies [View article]
a lot of pushback from WAG bears is that company lowered its cap ex outlook for the next few years and hence the company doesnt deserve as high a multiple as it used to get. that said, PE multiple drive off mkt share, too, not just growth, so the compresison should be offset as WAG and CVS continue to grab share. independent Rx stores are going by the wayside, as everyone knows. the last 2 years are evidence of this, as many were rolled up and many others folded after getting smoked by AWP rollbacks and/or depressed Medicaid reimbursments
these companies are blaming reform (GILD) and weather (DGX, LH) for soft volumes. Companies should have updated guidance mid qtr or after reform was passed - its pathetic on their behalf and even more sad how buyside is caught off guard by all of this
Forbes Speculates on Winners From Healthcare Reform Bill [View article]
HCA was smart to go private before the economy blew up and bad debt shot up, now that that that trend is presumably abating, they are going live at about 1-2x turns a higher EBITDA multiple (they were taken out at about 6x). Smartly, they reduced a lot of debt in the last 18 months and will be more feasible a stock for debt-averse PMs
Healthcare Reform Brings New Opportunity to Pharmacy Benefit Managers [View article]
@ Donald Johnson - medicaid and Medicare (at least on a Part D ASO basis; RDS is pretty profitable) are not the "big" markets for PBMs, so not sure what you are driving at. please elaborate
this article is greatly misinformed in that it suggest CVS/Caremark is not under "political scrutiny" and that the PBM business is on "neutral" political ground. Caremark has long been under the regulator's eye and the reform that just passed specifically has stuff in there that puts PBM practices (rebate transparency) under the microscope...
Big Two Medical Diagnostic Labs: Which Is the Best Investment? [View article]
PS - do you know how profitable the UNH biz was?? U said 7% of sales, what abt % of EBIT or earnings??
Lone Pine Starts Stake in Lincare [View article]
Almost Family Is Undervalued and Financially Sound [View article]
A Value Guy Looks at AmerisourceBergen [View article]
Specialty Pharmacies Play Growing Role in Patient Care [View article]
Teva and Walgreen: Two Solid Value Companies [View article]
Almost Family: Growth at a Reasonable Price [View article]
WellPoint Reports Improved Q1 Earnings [View article]
Reduced Volume Weighs on LabCorp [View article]
Forbes Speculates on Winners From Healthcare Reform Bill [View article]
Healthcare Reform Brings New Opportunity to Pharmacy Benefit Managers [View article]
Healthcare Reform Brings New Opportunity to Pharmacy Benefit Managers [View article]
Two Healthcare Stocks I Like Best [View article]
HMOs Try Accounting Acrobatics to Comply With Reforms [View article]
Aetna: Imminent Order to Suspend Medicare Advantage Enrollment [View article]